What is the catalog number for Imatinib (Mesylate)?

The catalog number for Imatinib (Mesylate) is HY-50946.

What sizes are available for Imatinib (Mesylate)?

Imatinib (Mesylate) is available in the following size(s): 200 mg, 10 mM - 1 mL, 500 mg, 1 g, 5 g.

How many pack sizes does Imatinib (Mesylate) come in?

Imatinib (Mesylate) is available in 5 different pack sizes.

Is Imatinib (Mesylate) in stock?

Imatinib (Mesylate) is currently made to order / not held in immediate stock. Contact us for lead time.

Who manufactures Imatinib (Mesylate)?

Imatinib (Mesylate) is manufactured by QuantiMol.

What is the estimated delivery time for Imatinib (Mesylate)?

Estimated delivery time for Imatinib (Mesylate) is approximately 15 business day(s), depending on your location.

Where can I find the safety data sheet (SDS/MSDS) for Imatinib (Mesylate)?

The safety data sheet for Imatinib (Mesylate) is available here: http://file.medchemexpress.com/batch_PDF/HY-50946/Imatinib-Mesylate-SDS-MedChemExpress.pdf.

How do I reconstitute this lyophilized product?

Reconstitution instructions, including the recommended diluent and final concentration, are provided on the datasheet. Aliquot immediately after reconstitution to avoid repeated freeze-thaw cycles.

What is the recommended incubation time for this antibody?

A suggested incubation time is provided in the recommended protocol on the datasheet, but may need adjusting depending on your sample type and detection system.

What should I check when this product first arrives?

Inspect the package immediately for transportation damage, ice loss, leakage, or breakage. Report any issues right away with photos and your order reference; our specialists will determine whether the product is still usable or needs replacing.

Imatinib (Mesylate)

Imatinib Mesylate (STI571 Mesylate) is a tyrosine kinases inhibitor that inhibits c-Kit, Bcr-Abl, and PDGFR (IC50=100 nM) tyrosine kinases.

Product Specifications

CAS Number

220127-57-1

Product Name Alternative

STI571 (Mesylate) ; CGP-57148B (Mesylate)

UNSPSC

12352005

Hazard Statement

H361

Target

Autophagy; Bcr-Abl; c-Kit; PDGFR

Type

Reference compound

Related Pathways

Autophagy; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Imatinib-Mesylate.html

Purity

99.98

Solubility

DMSO : 125 mg/mL (ultrasonic) |H2O : ≥ 50 mg/mL

Smiles

O=S(O)(C)=O.O=C(NC1=CC=C(C(NC2=NC=CC(C3=CC=CN=C3)=N2)=C1)C)C4=CC=C(CN5CCN(CC5)C)C=C4

Molecular Formula

C30H35N7O4S

Molecular Weight

589.71

Precautions

H361

References & Citations

[1]Heinrich MC, et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 2000 Aug 1;96 (3) :925-32.|[2]Guida T, et al. Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants. Clin Cancer Res. 2007 Jun 1;13 (11) :3363-9.|[3]Okuda K, et al. ARG tyrosine kinase activity is inhibited by STI571.Blood. 2001 Apr 15;97 (8) :2440-8|[4]Maj E, et al. Vitamin D Analogs Potentiate the Antitumor Effect of Imatinib Mesylate in a Human A549 Lung Tumor Model. Int J Mol Sci. 2015 Nov 13;16 (11) :27191-207.|[5]Tanaka S, et al. Protective Effects of Imatinib on Ischemia/Reperfusion Injury in Rat Lung. Ann Thorac Surg. 2016 Jul 23. pii: S0003-4975 (16) 30523-9|[6]Meirson T, et al. Targeting invadopodia-mediated breast cancer metastasis by using ABL kinase inhibitors. Oncotarget. 2018 Apr 24;9 (31) :22158-22183.